Spruce Biosciences
SPRB
36 hedge funds and large institutions have $28.5M invested in Spruce Biosciences in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 15 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.03% less ownership
Funds ownership: 72.76% → 69.73% (-3%)
16% less funds holding
Funds holding: 43 → 36 (-7)
17% less capital invested
Capital invested by funds: $34.4M → $28.5M (-$5.86M)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
60% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$325K |
| 2 |
Morgan Stanley
New York
|
+$84.2K |
| 3 |
E
Ergoteles
New York
|
+$71.6K |
| 4 |
Renaissance Technologies
New York
|
+$67.9K |
| 5 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$39.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$638K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$318K |
| 3 |
JP Morgan Chase
New York
|
-$194K |
| 4 |
State Street
Boston,
Massachusetts
|
-$192K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$113K |
SPRB Hedge Fund Activity: Q2 2022 in Review
36 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q2 2022, worth a combined $28.5M — down 17% from $34.4M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of SPRB and 6 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 6 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $325K. The largest seller was BlackRock, cutting an estimated $638K.
- 36 institutional investors held Spruce Biosciences (SPRB) as of Q2 2022, down from 43 in Q1 2022.
- Funds reported $28.5M of Spruce Biosciences stock for Q2 2022, down 17% quarter-over-quarter.
- 6 funds opened new Spruce Biosciences positions in Q2 2022 and 11 closed out, a net change of -5 holders.
- The largest Spruce Biosciences buyer in Q2 2022 was Millennium Management, an estimated $325K added.
- The largest Spruce Biosciences seller in Q2 2022 was BlackRock, an estimated $638K sold.
Based on aggregated 13F filings for Q2 2022.